DK2124933T3 - Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf - Google Patents

Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf

Info

Publication number: DK2124933T3
Authority: DK; Denmark
Prior art keywords: pharmaceutical compositions; therapeutic compound; tosylate salt; tosylate; salt
Prior art date: 2007-01-22

Application number

DK08702250.5T

Other languages

English (en)

Inventor

Travis T Wager

Todd William Butler

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-22

Filing date

2008-01-10

Publication date

2012-11-19

2008-01-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2012-11-19 Application granted granted Critical

2012-11-19 Publication of DK2124933T3 publication Critical patent/DK2124933T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK08702250.5T 2007-01-22 2008-01-10 Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf DK2124933T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88593107P	2007-01-22	2007-01-22
PCT/IB2008/000088 WO2008090429A1 (en)	2007-01-22	2008-01-10	Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number	Publication Date
DK2124933T3 true DK2124933T3 (da)	2012-11-19

Family

ID=39277093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08702250.5T DK2124933T3 (da)	2007-01-22	2008-01-10	Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf

Country Status (25)

Country	Link
US (1)	US8314139B2 (da)
EP (1)	EP2124933B1 (da)
JP (1)	JP4585610B2 (da)
KR (1)	KR101108109B1 (da)
CN (1)	CN101631545B (da)
AR (1)	AR064963A1 (da)
AU (1)	AU2008208653B2 (da)
BR (1)	BRPI0806473A2 (da)
CA (1)	CA2676456C (da)
CL (1)	CL2008000180A1 (da)
DK (1)	DK2124933T3 (da)
ES (1)	ES2395744T3 (da)
HK (1)	HK1137660A1 (da)
IL (1)	IL199587A (da)
MX (1)	MX2009007782A (da)
NZ (1)	NZ577951A (da)
PE (1)	PE20081690A1 (da)
PL (1)	PL2124933T3 (da)
PT (1)	PT2124933E (da)
RU (1)	RU2430099C2 (da)
SI (1)	SI2124933T1 (da)
TW (1)	TWI358294B (da)
UY (1)	UY30878A1 (da)
WO (1)	WO2008090429A1 (da)
ZA (1)	ZA200905827B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
US9108948B2 (en) *	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
CN103382174A (zh) *	2006-06-23	2013-11-06	雅培制药有限公司	作为组胺h3受体调节物的环丙胺衍生物
WO2009071988A1 (en) *	2007-12-07	2009-06-11	Pfizer Inc.	Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
US8383657B2 (en) *	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) *	2007-12-21	2009-09-03	Abbott Laboratories	Compositions for treatment of cognitive disorders
US9186353B2 (en) *	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8853390B2 (en)	2010-09-16	2014-10-07	Abbvie Inc.	Processes for preparing 1,2-substituted cyclopropyl derivatives
JP5767393B2 (ja)	2011-03-31	2015-08-19	ファイザー・インク	新規二環式ピリジノン
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
WO2013030713A1 (en)	2011-08-31	2013-03-07	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
ES2426539B1 (es) *	2012-04-18	2014-09-09	Dr Healthcare España, S. L.	Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
BR112014032913A2 (pt)	2012-06-29	2017-06-27	Pfizer	novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
JP2015529239A (ja)	2012-09-20	2015-10-05	ファイザー・インク	アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
CN103113405B (zh) *	2012-10-17	2016-03-02	上海日馨生物科技有限公司	苯磷硫胺多晶型体、制备方法及其应用
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
WO2014091352A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru)	2013-02-19	2016-03-31	Пфайзер Инк.	Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
JP6425717B2 (ja)	2013-10-04	2018-11-21	ファイザー・インク	ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
EP3083618B1 (en)	2013-12-17	2018-02-21	Pfizer Inc	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CR20160454A (es)	2014-04-01	2016-12-06	Pfizer	CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
SG11201607896YA (en)	2014-04-10	2016-10-28	Pfizer	2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (en)	2014-07-24	2020-01-15	Pfizer Inc	Pyrazolopyrimidine compounds
AU2015298378B2 (en)	2014-08-06	2018-08-02	Pfizer Inc.	Imidazopyridazine compounds
MX368391B (es)	2015-02-03	2019-09-30	Pfizer	Ciclopropabenzofuranil-piridopirazindionas novedosas.
UA125334C2 (uk)	2015-06-17	2022-02-23	Пфайзер Інк.	Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази
WO2017046675A1 (en)	2015-09-14	2017-03-23	Pfizer Inc.	Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
WO2017051276A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018534251A (ja)	2015-09-24	2018-11-22	ファイザー・インク	Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
DK3419979T3 (da)	2016-02-23	2020-03-23	Pfizer	6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser
WO2018002760A1 (en)	2016-07-01	2018-01-04	Pfizer Inc.	5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
NZ757971A (en)	2017-03-10	2024-12-20	Pfizer	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
EP3592740B1 (en)	2017-03-10	2022-02-09	Pfizer Inc.	Cyclic substituted imidazo[4,5-c]quinoline derivatives
CA3066077A1 (en)	2017-06-07	2018-12-13	Adrx, Inc.	Tau aggregation inhibitors
BR112019026955A2 (pt)	2017-06-22	2020-06-30	Pfizer Inc.	derivados de di-hidro-pirrolo-piridina
WO2019036725A2 (en)	2017-08-18	2019-02-21	Adrx, Inc.	PEPTIDE INHIBITORS OF TAU AGGREGATION
TWI801540B (zh)	2018-03-23	2023-05-11	美商輝瑞大藥廠	哌嗪氮雜螺衍生物
EP4297868A4 (en)	2021-02-23	2025-01-08	Hoth Therapeutics Inc	USE OF APREPITANT FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6559140B2 (en)	2000-03-09	2003-05-06	Abbott Laboratories	Cyclic and bicyclic diamino histamine-3 receptor antagonists
EP1720847A1 (en) *	2004-02-02	2006-11-15	Pfizer Products Incorporated	Histamine-3 receptor modulators
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
WO2009071988A1 (en)	2007-12-07	2009-06-11	Pfizer Inc.	Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide

2008
- 2008-01-10 RU RU2009124541/04A patent/RU2430099C2/ru not_active IP Right Cessation
- 2008-01-10 ES ES08702250T patent/ES2395744T3/es active Active
- 2008-01-10 PT PT87022505T patent/PT2124933E/pt unknown
- 2008-01-10 AU AU2008208653A patent/AU2008208653B2/en not_active Ceased
- 2008-01-10 DK DK08702250.5T patent/DK2124933T3/da active
- 2008-01-10 BR BRPI0806473-3A patent/BRPI0806473A2/pt not_active IP Right Cessation
- 2008-01-10 EP EP08702250A patent/EP2124933B1/en not_active Not-in-force
- 2008-01-10 NZ NZ577951A patent/NZ577951A/en not_active IP Right Cessation
- 2008-01-10 SI SI200830802T patent/SI2124933T1/sl unknown
- 2008-01-10 JP JP2009546829A patent/JP4585610B2/ja not_active Expired - Fee Related
- 2008-01-10 MX MX2009007782A patent/MX2009007782A/es active IP Right Grant
- 2008-01-10 PL PL08702250T patent/PL2124933T3/pl unknown
- 2008-01-10 WO PCT/IB2008/000088 patent/WO2008090429A1/en active Application Filing
- 2008-01-10 CN CN2008800028688A patent/CN101631545B/zh not_active Expired - Fee Related
- 2008-01-10 CA CA2676456A patent/CA2676456C/en not_active Expired - Fee Related
- 2008-01-10 KR KR1020097015310A patent/KR101108109B1/ko not_active IP Right Cessation
- 2008-01-18 AR ARP080100236A patent/AR064963A1/es unknown
- 2008-01-18 US US12/016,521 patent/US8314139B2/en not_active Expired - Fee Related
- 2008-01-21 UY UY030878A patent/UY30878A1/es not_active Application Discontinuation
- 2008-01-21 TW TW097102227A patent/TWI358294B/zh not_active IP Right Cessation
- 2008-01-21 PE PE2008000164A patent/PE20081690A1/es not_active Application Discontinuation
- 2008-01-22 CL CL200800180A patent/CL2008000180A1/es unknown
2009
- 2009-06-25 IL IL199587A patent/IL199587A/en not_active IP Right Cessation
- 2009-08-21 ZA ZA200905827A patent/ZA200905827B/xx unknown
2010
- 2010-03-19 HK HK10102903.0A patent/HK1137660A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP2124933B1 (en)	2012-10-17
TW200838499A (en)	2008-10-01
HK1137660A1 (en)	2010-08-06
US8314139B2 (en)	2012-11-20
AR064963A1 (es)	2009-05-06
ZA200905827B (en)	2010-05-26
CN101631545B (zh)	2013-03-13
BRPI0806473A2 (pt)	2011-09-27
AU2008208653A1 (en)	2008-07-31
RU2009124541A (ru)	2011-02-27
IL199587A0 (en)	2010-03-28
US20080176925A1 (en)	2008-07-24
MX2009007782A (es)	2009-07-31
CA2676456C (en)	2012-03-27
SI2124933T1 (sl)	2012-12-31
KR101108109B1 (ko)	2012-02-06
PT2124933E (pt)	2013-01-07
RU2430099C2 (ru)	2011-09-27
WO2008090429A1 (en)	2008-07-31
IL199587A (en)	2014-06-30
PE20081690A1 (es)	2008-11-28
ES2395744T3 (es)	2013-02-14
NZ577951A (en)	2012-02-24
JP2010516749A (ja)	2010-05-20
AU2008208653B2 (en)	2012-11-22
CA2676456A1 (en)	2008-07-31
CN101631545A (zh)	2010-01-20
UY30878A1 (es)	2009-08-31
PL2124933T3 (pl)	2013-02-28
JP4585610B2 (ja)	2010-11-24
TWI358294B (en)	2012-02-21
CL2008000180A1 (es)	2008-08-01
KR20090101948A (ko)	2009-09-29
EP2124933A1 (en)	2009-12-02

Publication	Publication Date	Title
DK2124933T3 (da)	2012-11-19	Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf
LTC2140867I2 (lt)	2018-11-12	Farmacinė kompozicija
DK1962817T3 (da)	2011-03-07	Transdermal tilførsel af et salt af meptazinol
DK2011486T3 (da)	2012-09-03	Farmaceutiske sammensætninger af rifaximin
DK3492069T3 (da)	2022-03-14	Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2180882T3 (da)	2013-05-27	Farmaceutisk faststofsammensætning af matrix-type
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
NL300998I2 (nl)	2019-08-28	Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
DK2220116T3 (da)	2012-11-26	Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
BRPI0819232A2 (pt)	2016-11-01	composto heterocíclico e composição farmacêutica do mesmo
BRPI0905952A2 (pt)	2015-06-30	Composto e sais do mesmo e compição farmacêutica
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
DK2185164T3 (da)	2017-11-13	Sammensætning og terapeutisk antitumorvaccine
PL2152237T3 (pl)	2016-06-30	Nowa kompozycja farmaceutyczna
DK2318004T3 (da)	2013-07-08	Farmaceutiske sammensætninger indeholdende krystalform Y af posaconazol
BRPI0905680A2 (pt)	2015-07-07	"composição farmacêutica de uma composição farmacêutica"
DK2356093T3 (da)	2013-04-22	Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
DK2154966T3 (da)	2013-11-18	Benzimidazoler og farmaceutiske sammensætninger deraf
BRPI0817833A2 (pt)	2015-03-31	Composição farmacêutica antimalárica
BRPI0820198A2 (pt)	2019-09-24	composições farmacêuticas
DK2152699T3 (da)	2011-04-18	Quinolon-forbindelse og farmaceutisk sammensætning
DK2175849T3 (da)	2013-05-13	Behandling af melanomer
DK2155255T3 (da)	2013-09-02	Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
DK2121138T3 (da)	2017-01-02	Terapeutiske anvendelser af eslicarbazepin